TY  - JOUR
AU  - Sannemann, Lena
AU  - Schild, Ann-Katrin
AU  - Altenstein, Slawek
AU  - Bartels, Claudia
AU  - Brosseron, Frederic
AU  - Bürger, Katharina
AU  - Cosma, Nicoleta Carmen
AU  - Fliessbach, Klaus
AU  - Freiesleben, Silka Dawn
AU  - Glanz, Wenzel
AU  - Heneka, Michael T.
AU  - Janowitz, Daniel
AU  - Kilimann, Ingo
AU  - Kobeleva, Xenia
AU  - Laske, Christoph
AU  - Metzger, Coraline D.
AU  - Munk, Matthias H. J.
AU  - Perneczky, Robert
AU  - Peters, Oliver
AU  - Polcher, Alexandra
AU  - Priller, Josef
AU  - Rauchmann, Boris
AU  - Rösch, Christina
AU  - Rudolph, Janna
AU  - Schneider, Anja
AU  - Spottke, Annika
AU  - Spruth, Eike Jakob
AU  - Teipel, Stefan
AU  - Vukovich, Ruth
AU  - Wagner, Michael
AU  - Wiltfang, Jens
AU  - Wolfsgruber, Steffen
AU  - Düzel, Emrah
AU  - Jessen, Frank
TI  - Neuropsychiatric symptoms in at-risk groups for AD dementia and their association with worry and AD biomarkers—results from the DELCODE study
JO  - Alzheimer's research & therapy
VL  - 12
IS  - 1
SN  - 1758-9193
CY  - London
PB  - BioMed Central
M1  - DZNE-2021-00063
SP  - 131
PY  - 2020
AB  - BackgroundEarly identification of individuals at risk of dementia is mandatory to implement prevention strategies and design clinical trials that target early disease stages. Subjective cognitive decline (SCD) and neuropsychiatric symptoms (NPS) have been proposed as potential markers for early manifestation of Alzheimer’s disease (AD). We aimed to investigate the frequency of NPS in SCD, in other at-risk groups, in healthy controls (CO), and in AD patients, and to test the association of NPS with AD biomarkers, with a particular focus on cognitively unimpaired participants with or without SCD-related worries.MethodsWe analyzed data of n = 687 participants from the German DZNE Longitudinal Cognitive Impairment and Dementia (DELCODE) study, including the diagnostic groups SCD (n = 242), mild cognitive impairment (MCI, n = 115), AD (n = 77), CO (n = 209), and first-degree relatives of AD patients (REL, n = 44). The Neuropsychiatric Inventory Questionnaire (NPI-Q), Geriatric Depression Scale (GDS-15), and Geriatric Anxiety Inventory (GAI-SF) were used to assess NPS. We examined differences of NPS frequency between diagnostic groups. Logistic regression analyses were carried out to further investigate the relationship between NPS and cerebrospinal fluid (CSF) AD biomarkers, focusing on a subsample of cognitively unimpaired participants (SCD, REL, and CO), who were further differentiated based on reported worries.ResultsThe numbers of reported NPS, depression scores, and anxiety scores were significantly higher in subjects with SCD compared to CO. The quantity of reported NPS in subjects with SCD was lower compared to the MCI and AD group. In cognitively unimpaired subjects with worries, low Aß42 was associated with higher rates of reporting two or more NPS (OR 0.998, 95
KW  - Aged
KW  - Alzheimer Disease: epidemiology
KW  - Anxiety: epidemiology
KW  - Biomarkers
KW  - Cognitive Dysfunction: epidemiology
KW  - Humans
KW  - Longitudinal Studies
KW  - Neuropsychological Tests
LB  - PUB:(DE-HGF)16
C2  - pmc:PMC7566134
C6  - pmid:33066827
DO  - DOI:10.1186/s13195-020-00701-7
UR  - https://pub.dzne.de/record/154201
ER  -